These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 9021441)

  • 21. The concentration of atrial and brain natriuretic peptide in patients with idiopathic hypertension.
    Irzmanski R; Barylski M; Banach M; Piechota M; Kowalski J; Cierniewski C; Pawlicki L
    Med Sci Monit; 2007 Oct; 13(10):CR449-56. PubMed ID: 17901852
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension.
    Nishikimi T; Yoshihara F; Morimoto A; Ishikawa K; Ishimitsu T; Saito Y; Kangawa K; Matsuo H; Omae T; Matsuoka H
    Hypertension; 1996 Jul; 28(1):22-30. PubMed ID: 8675258
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
    Palmieri V; Devereux RB
    Minerva Cardioangiol; 2002 Jun; 50(3):169-74. PubMed ID: 12107398
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The effect of angiotensin-converting enzyme inhibitors on left ventricular hypertrophy in patients with chronic glomerulonephritis and pronounced kidney failure].
    Diadyk AI; Bagriĭ AE; Lebed' IA; Iarovaia NF; Shchukina EV; Gaĭdukov VO; Gritsenko PV; Diadyk IA
    Ter Arkh; 1997; 69(6):24-7. PubMed ID: 9297267
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Atrial natriuretic peptide helps prevent late remodeling after left ventricular aneurysm repair.
    Tsuneyoshi H; Nishina T; Nomoto T; Kanemitsu H; Kawakami R; Unimonh O; Nishimura K; Komeda M
    Circulation; 2004 Sep; 110(11 Suppl 1):II174-9. PubMed ID: 15364859
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Effect of enalapril on left ventricular hypertrophy and left ventricular function in patients with hypertension].
    Kakinoki S; Takechi S; Hashimoto M; Sakuma I; Nomura A; Kitabatake A; Yasuda H
    Kokyu To Junkan; 1993 Dec; 41(12):1185-9. PubMed ID: 8284542
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effects of renin-angiotensin system blockers on left ventricular hypertrophy and biochemical markers of collagen balance in patients with hypertensive hypertrophy].
    Ovchinnikov AG; Serbul VM; Ageev FT
    Ter Arkh; 2009; 81(5):64-71. PubMed ID: 19537590
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Cardiac natriuretic peptides as markers of left ventricular dysfunction].
    Omland T; Aakvaag A; Vik-Mo H
    Tidsskr Nor Laegeforen; 1997 Mar; 117(7):943-8. PubMed ID: 9103004
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Atrial and brain natriuretic peptide and endothelin-1 concentration in patients with idiopathic arterial hypertension: the dependence on the selected morphological parameters.
    Irzmański R; Banach M; Piechota M; Kowalski J; Barylski M; Cierniewski C; Pawlicki L
    Clin Exp Hypertens; 2007 Apr; 29(3):149-64. PubMed ID: 17497342
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Usefulness of temporal changes in neurohormones as markers of ventricular remodeling and prognosis in patients with left ventricular systolic dysfunction and heart failure receiving either candesartan or enalapril or both.
    Yan RT; White M; Yan AT; Yusuf S; Rouleau JL; Maggioni AP; Hall C; Latini R; Afzal R; Floras J; Masson S; McKelvie RS;
    Am J Cardiol; 2005 Sep; 96(5):698-704. PubMed ID: 16125499
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Brain and atrial natriuretic peptides: a dual peptide system of potential importance in sodium balance and blood pressure regulation in patients with essential hypertension.
    Buckley MG; Markandu ND; Sagnella GA; MacGregor GA
    J Hypertens; 1994 Jul; 12(7):809-13. PubMed ID: 7963510
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Regression of hypertensive heart hypertrophy caused by chronic angiotensin-converting enzyme inhibition].
    Motz W; Strauer BE
    Z Kardiol; 1988 Jan; 77(1):53-60. PubMed ID: 2834885
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hormonal and renal differences between low dose and high dose angiotensin converting enzyme inhibitor treatment in patients with chronic heart failure.
    Davidson NC; Coutie WJ; Webb DJ; Struthers AD
    Heart; 1996 Jun; 75(6):576-81. PubMed ID: 8697160
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exaggerated atrial natriuretic peptide release during acute exercise in essential hypertension.
    Sudhir K; Woods RL; Jennings GL; Nelson LA; Laufer E; Korner PI
    J Hum Hypertens; 1988 Mar; 1(4):299-304. PubMed ID: 2975706
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma concentrations and comparisons of brain and atrial natriuretic peptide in normal subjects and in patients with essential hypertension.
    Buckley MG; Markandu ND; Miller MA; Sagnella GA; MacGregor GA
    J Hum Hypertens; 1993 Jun; 7(3):245-50. PubMed ID: 8345491
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relations of diastolic left ventricular filling to systolic chamber and myocardial contractility in hypertensive patients with left ventricular hypertrophy (The PRESERVE Study).
    Palmieri V; Bella JN; DeQuattro V; Roman MJ; Hahn RT; Dahlof B; Sharpe N; Lau CP; Chen WC; Paran E; de Simone G; Devereux RB
    Am J Cardiol; 1999 Sep; 84(5):558-62. PubMed ID: 10482155
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of ACE inhibition on left ventricular dimensions and haemodynamics in systemic hypertension: a radionuclide and echocardiographic study.
    Haznedaroglu IC; Erdem Y; Tokgözoglu L; Caglar M; Kes S; Sayinalp NM; Yörükan S
    Cent Afr J Med; 1995 Apr; 41(4):118-23. PubMed ID: 7788682
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential regulation of cardiac adrenomedullin and natriuretic peptide gene expression by AT1 receptor antagonism and ACE inhibition in normotensive and hypertensive rats.
    Magga J; Kalliovalkama J; Romppanen H; Vuolteenaho O; Pörsti I; Kähönen M; Tolvanen JP; Ruskoaho H
    J Hypertens; 1999 Nov; 17(11):1543-52. PubMed ID: 10608466
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiovascular structural changes and calcium antagonist therapy in patients with hypertension.
    Agabiti-Rosei E; Muiesan ML; Rizzoni D; Zulli R; Calebich S; Castellano M; Cavaliere G; Nordio G; Pasini F; Zuccato F
    J Cardiovasc Pharmacol; 1994; 24 Suppl A():S37-43. PubMed ID: 7603076
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy.
    Yamamoto K; Burnett JC; Jougasaki M; Nishimura RA; Bailey KR; Saito Y; Nakao K; Redfield MM
    Hypertension; 1996 Dec; 28(6):988-94. PubMed ID: 8952587
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.